NCT00724893View on ClinicalTrials.gov

Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)

CompletedOBSERVATIONAL
Enrollment

2,430

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Hepatitis C, ChronicHepatitis C
Interventions
BIOLOGICAL

PegIFN-2b

PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling

DRUG

Ribavirin

Ribavirin capsules administered orally. Dosing in accordance with approved labelling.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00724893 - Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) | Biotech Hunter | Biotech Hunter